Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A master protocol to investigate a novel therapy acetyl-L-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 Gangliosidoses, and Ataxia Telangiectasia

View ORCID ProfileT. Fields, View ORCID ProfileM. Patterson, View ORCID ProfileT. Bremova, G. Belcher, I. Billington, View ORCID ProfileG.C. Churchill, W. Davis, W. Evans, S. Flint, View ORCID ProfileA. Galione, U. Granzer, J. Greenfield, R. Karl, R. Kay, D. Lewi, T. Mathieson, T. Meyer, D. Pangonis, View ORCID ProfileF.M. Platt, L. Tsang, C. Verburg, M. Factor, View ORCID ProfileM. Strupp
doi: https://doi.org/10.1101/2020.03.11.20034256
T. Fields
1IntraBio Ltd, Begbroke Science Park, Begroke Hill, Woodstock Road, Oxford OX5 1PF, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for T. Fields
  • For correspondence: tfields@intrabio.com Michael.Strupp@med.uni-muenchen.de
M. Patterson
2Mayo Clinic, 200 First Street SW, Rochester MN 55905, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for M. Patterson
T. Bremova
3Department of Neurology, Inselspital, University Hospital Bern, and University of Bern, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for T. Bremova
G. Belcher
4PV Consultancy, 113 St Georges Square Mews, London SW1V 3RZ, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I. Billington
1IntraBio Ltd, Begbroke Science Park, Begroke Hill, Woodstock Road, Oxford OX5 1PF, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G.C. Churchill
5Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for G.C. Churchill
W. Davis
6Ataxia-Telangiectasia Society, Rothamsted Experimental Station West Common, Harpenden AL5 2JQ, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. Evans
7Niemann-Pick UK, Suite 2, Vermont House, Concord, Washington, Tyne and Wear, NE37 2SQ; Primary Care Stratified Medicine (PRISM), Division of Primary Care, University of Nottingham, Nottingham
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Flint
1IntraBio Ltd, Begbroke Science Park, Begroke Hill, Woodstock Road, Oxford OX5 1PF, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Galione
5Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for A. Galione
U. Granzer
8Granzer Regulatory Consulting & Services, Kistlerhofstr. 172C, D-81379 München, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Greenfield
9Ataxia UK, 12 Broadbent close, London N6 5JW, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Karl
10Cure Tay-Sachs Foundation 2409 E. Luke Avenue, Phoenix AZ, 85016, Unites States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Kay
11RK Statistics, Brook House, Mesne Lane, Bakewell DE45 1AL, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Lewi
12The Cure & Action for Tay-Sachs (CATS) Foundation, 94 Milborough Crescent, Lee, London SE12 0RW, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Mathieson
13International Niemann-Pick Disease Alliance, Suite 2, Vermont House, Concord, Washington, Tyne and Wear, NE37 2SQ, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Meyer
8Granzer Regulatory Consulting & Services, Kistlerhofstr. 172C, D-81379 München, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Pangonis
14National Tay-Sachs and Allied Disease Foundation; 2001 Beacon Street, Suite 204, Boston, MA 02135, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F.M. Platt
5Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for F.M. Platt
L. Tsang
15Arnold & Porter Kaye Scholer LLP, 25 Old Broad Street | London EC2N 1HQ, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Verburg
1IntraBio Ltd, Begbroke Science Park, Begroke Hill, Woodstock Road, Oxford OX5 1PF, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Factor
1IntraBio Ltd, Begbroke Science Park, Begroke Hill, Woodstock Road, Oxford OX5 1PF, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Strupp
16Department of Neurology and German Center for Vertigo and Balance Disorders, Ludwig Maximilians University, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for M. Strupp
  • For correspondence: tfields@intrabio.com Michael.Strupp@med.uni-muenchen.de
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background The lack of approved treatments for the majority of rare diseases is reflective of the unique challenges of orphan drug development. Novel methodologies, including new functionally relevant endpoints, are needed to render the development process more feasible and appropriate for these rare populations, and thereby expedite the approval of promising treatments to address patients’ high unmet medical need. Here, we describe the development of an innovative master protocol and primary outcome assessment to investigate the modified amino acid N-acetyl-L-leucine (Sponsor Code: IB1001) in three seperate, multinational, phase II trials for three ultra-rare, autosomal-recessive, neurodegenerative disorders: Niemann-Pick disease type C (NPC), GM2 Gangliosidoses (Tay-Sachs and Sandhoff disease; “GM2”), and Ataxia Telangiectasia (A-T).

Methods/design The innovative IB1001 master protocol and novel CI-CS primary endpoints were developed through a close collaboration between the Industry Sponsor, Key Opinion Leaders, representatives of the Patient Communities, and National Regulatory Authorities. As a result, the open-label, rater-blinded study design is considerate of the practical limitations of recruitment and retention of subjects in these ultra-orphan populations. The novel primary endpoint, the Clinical Impression of Change in Severity© (CI-CS), accommodates the heterogenous clinical presentation of NPC, GM2, and A-T: at screening, the Principal Investigator appoints for each patient a primary anchor test (either the 8 Meter Walk Test (8MWT) or 9 Hole Peg Test of the Dominant Hand (9HPT-D)) based on his/her unique clinical symptoms. The anchor tests are videoed in a standardized manner at each visit to capture all aspects related to the patient’s functional performance. The CI-CS assessment is ultimately performed by independent, blinded raters who compare videos of the primary anchor test from three periods: baseline, the end of treatment, and the end of a post-treatment washout. Blinded to the timepoint of each video, the raters make an objective comparison scored on a 7-point Likert scale of the change in the severity of the patient’s neurological signs and symptoms from Video A to Video B. To investigate both the symptomatic and disease-modifying effects of treatment, N-acetyl-L-leucine is assessed during two treatment sequences: a 6-week parent study, and one-year extension phase.

Discussion The novel CI-CS assessment, developed through a collaboration of all stakeholders, is advantageous in that it better ensures the primary endpoint is functionally relevant for each patient, is able to capture small but meaningful clinical changes critical to the patients’ quality of life (fine-motor skills; gait), and blinds the primary outcome assessment. The results of these three trials will inform whether N-acetyl-L-leucine is an effective treatment for NPC, GM2, and A-T, and can also serve as a new therapeutic paradigm for the development of future treatments for other orphan diseases.

Trial registrations The three trials (IB1001-201 for Niemann-Pick disease type C (NPC); IB1001-202 for GM2 Gangliosidoses (Tay-Sachs and Sandhoff); IB1001-203 for Ataxia-Telangiectasia (A-T)) have been registered at www.clinicaltrials.gov (NCT03759639; NCT03759665; NCT03759678), www.clinicaltrialsregister.eu (EudraCT: 2018-004331-71; 2018-004406-25; 2018-004407-39) and https://www.germanctr.de (DR KS-ID: DRKS00016567; DRKS00017539; DRKS00020511).

Competing Interest Statement

MF is a co-founder, shareholder, and Chairman of IntraBio. TF and IB are officers and shareholders of IntraBio. FP is a cofounder, shareholder, and consultant to IntraBio and consultant to Actelion and Orphazyme. MS is a shareholder to IntraBio, and consultant for Abbott, Actelion, AurisMedical, Heel, IntraBio and Sensorion; he has received speaker's honoraria from Abbott, Actelion, Auris Medical, Biogen, Eisai, Grünenthal, GSK, Henning Pharma, Interacoustics, Johnson & Johnson, MSD, Otometrics, Pierre-Fabre, TEVA, UCB. AG and GC are cofounders, shareholders and consultants to IntraBio. MP is a shareholder of IntraBio, and has received consulting fees, honoraria and research grants from Actelion Pharmaceuticals Ltd. and Biomarin. CV, SF are consultants and shareholders of IntraBio. UG, TM, GB, and RKay are consultants to IntraBio. TBE received honoraria for lecturing from Actelion and Sanofi Genzyme. IntraBio owns patents EP3359146 and EP3416631 (related to treatment of lysosomal storage disorders and neurodegenerative diseases with Acetyl-Leucine and its analogues). IntraBio has pending patent applications EP19174007.5, EP3482754, PCT/US2018/056420, PCT/US2018/018420, PCT/IB2018/054676, PCT/IB2019/051214, PCT/IB2017/054928, PCT/GB2017/051090, PCT/IB2017/054929, USPTO 62/812,987, USPTO 62/842,296, USPTO 62/888,894, USPTO 62/895,144, USPTO 62/868,383, USPTO 62/931,003, USPTO 62/960,637, and PCT/IB2019/060525 relating to treatment of lysosomal storage disorders, neurodegenerative diseases and neurodegeneration with Acetyl-leucine and its analogues.

Clinical Trial

www.clinicaltrials.gov (NCT03759639; NCT03759665; NCT03759678); www.clinicaltrialsregister.eu (EudraCT: 2018-004331-71; 2018-004406-25; 2018-004407-39); and https://www.germanctr.de (DR KS-ID: DRKS00016567; DRKS00017539; DRKS00020511)

Funding Statement

This study was financially supported by IntraBio (https://intrabio.com).

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Email addresses: tfields{at}intrabio.com, patterson.marc{at}mayo.edu, tatiana.bremova-ertl{at}extern.insel.ch, glynbelcher{at}pvconsult.co.uk, ian{at}intrabio.co.uk, grant.churchill{at}pharm.ox.ac.uk, william{at}atsociety.org.uk, will{at}npuk.org, sflint{at}intrabio.com, antony.galione{at}pharm.ox.ac.uk, granzer{at}granzer.biz, jgreenfield{at}ataxia.org.uk rick.karl{at}curetay-sachs.org, richard.kay{at}rkstatistics.com, dan{at}cats-foundation.org, toni.mathieson{at}inpda.org, meyer{at}granzer.biz, diana{at}ntsad.org, frances.platt{at}pharm.ox.ac.uk, lincoln.tsang{at}arnoldporter.com, cverburg{at}intrabio.com, mfactor{at}intrabio.com, michael.Strupp{at}med.uni-muenchen.de

Data Availability

Not applicable as the study is a trial design and data will be published after the trials are complete.

  • List of abbreviations

    8MWT
    8-meter walk test
    9HPT-D
    9-hole peg test of the dominant hand
    A-T
    Ataxia Telangiectasia
    CI-CS
    clinical impression of change in severity
    CI-S
    clinical impression of severity
    DSMB
    Data Safety Monitoring Board
    EQ-QoL
    Euro Quality of Life
    EP
    Extension Phase
    FDA
    Food and Drug Administration
    GM2
    GM2 Gangliosidoses
    mITT
    modified intention to treat
    mDRS
    Modified Disability Rating Scale
    NPC
    Niemann-Pick type C
    NPC-CSS
    NPC clinical severity scale
    PI
    principal investigator
    SARA
    Scale for the Assessment and Rating of Ataxia
    SCAFI
    Spinocerebellar Ataxia Functional Index.
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
    Back to top
    PreviousNext
    Posted March 20, 2020.
    Download PDF
    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    A master protocol to investigate a novel therapy acetyl-L-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 Gangliosidoses, and Ataxia Telangiectasia
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    A master protocol to investigate a novel therapy acetyl-L-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 Gangliosidoses, and Ataxia Telangiectasia
    T. Fields, M. Patterson, T. Bremova, G. Belcher, I. Billington, G.C. Churchill, W. Davis, W. Evans, S. Flint, A. Galione, U. Granzer, J. Greenfield, R. Karl, R. Kay, D. Lewi, T. Mathieson, T. Meyer, D. Pangonis, F.M. Platt, L. Tsang, C. Verburg, M. Factor, M. Strupp
    medRxiv 2020.03.11.20034256; doi: https://doi.org/10.1101/2020.03.11.20034256
    Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    Citation Tools
    A master protocol to investigate a novel therapy acetyl-L-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 Gangliosidoses, and Ataxia Telangiectasia
    T. Fields, M. Patterson, T. Bremova, G. Belcher, I. Billington, G.C. Churchill, W. Davis, W. Evans, S. Flint, A. Galione, U. Granzer, J. Greenfield, R. Karl, R. Kay, D. Lewi, T. Mathieson, T. Meyer, D. Pangonis, F.M. Platt, L. Tsang, C. Verburg, M. Factor, M. Strupp
    medRxiv 2020.03.11.20034256; doi: https://doi.org/10.1101/2020.03.11.20034256

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Pharmacology and Therapeutics
    Subject Areas
    All Articles
    • Addiction Medicine (62)
    • Allergy and Immunology (142)
    • Anesthesia (46)
    • Cardiovascular Medicine (411)
    • Dentistry and Oral Medicine (68)
    • Dermatology (47)
    • Emergency Medicine (141)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
    • Epidemiology (4839)
    • Forensic Medicine (3)
    • Gastroenterology (180)
    • Genetic and Genomic Medicine (674)
    • Geriatric Medicine (70)
    • Health Economics (191)
    • Health Informatics (624)
    • Health Policy (318)
    • Health Systems and Quality Improvement (203)
    • Hematology (85)
    • HIV/AIDS (156)
    • Infectious Diseases (except HIV/AIDS) (5312)
    • Intensive Care and Critical Care Medicine (328)
    • Medical Education (93)
    • Medical Ethics (24)
    • Nephrology (75)
    • Neurology (684)
    • Nursing (42)
    • Nutrition (113)
    • Obstetrics and Gynecology (126)
    • Occupational and Environmental Health (204)
    • Oncology (439)
    • Ophthalmology (140)
    • Orthopedics (36)
    • Otolaryngology (89)
    • Pain Medicine (35)
    • Palliative Medicine (16)
    • Pathology (128)
    • Pediatrics (193)
    • Pharmacology and Therapeutics (131)
    • Primary Care Research (84)
    • Psychiatry and Clinical Psychology (777)
    • Public and Global Health (1808)
    • Radiology and Imaging (323)
    • Rehabilitation Medicine and Physical Therapy (138)
    • Respiratory Medicine (255)
    • Rheumatology (86)
    • Sexual and Reproductive Health (69)
    • Sports Medicine (61)
    • Surgery (100)
    • Toxicology (23)
    • Transplantation (29)
    • Urology (37)